Postpartum Depression: Signs, Screening, Breastfeeding and Evidence-Based Treatment

Evidence reviewed: 8 November 2026. Postpartum depression (PPD) is a depressive illness that can develop after childbirth and seriously affect mood, sleep, relationships and everyday functioning. Depression can also begin during pregnancy; together, these conditions are termed perinatal depression. PPD is treatable. Effective care includes psychotherapy, appropriate antidepressants, practical support and, for selected adults, postpartum-depression-specific medicines. Early recognition matters, especially when there are thoughts of self-harm, inability to care for oneself or the infant, or symptoms of postpartum psychosis [1–4].

Postpartum depression versus the baby blues

Short-lived mood swings, tearfulness or anxiety during the first days after delivery are common. The “baby blues” typically improve within about two weeks with reassurance, rest and practical support. Postpartum depression is more severe or persistent and may begin during pregnancy or at any time in the first year after childbirth [1,2].

Feature Baby blues Postpartum depression
Timing Usually first days after birth May begin during pregnancy or within the first postpartum year
Duration Generally resolves within two weeks Often lasts longer, worsens or causes substantial impairment
Symptoms Brief tearfulness, irritability and mood changes Persistent sadness, anxiety, loss of pleasure, hopelessness or impaired functioning
Management Support and observation; seek help if persistent or severe Clinical assessment and individualized treatment

Do not wait two weeks to seek care if symptoms are severe, rapidly worsening or dangerous. Persistent inability to sleep even when the baby is cared for, despair or thoughts of suicide deserve prompt assessment [1].

Signs and symptoms of postpartum depression

  • Low mood, tearfulness, hopelessness or loss of interest most of the day.
  • Excessive guilt, worthlessness or feeling unable to cope with everyday needs.
  • Anxiety, agitation, irritability or frightening worries about the baby’s health or safety.
  • Sleep disturbance that exceeds ordinary interrupted infant-care sleep, or inability to rest when the opportunity exists.
  • Changes in appetite, energy and concentration.
  • Difficulty connecting with the infant, emotional numbness or withdrawal from family and friends.
  • Thoughts about death, self-harm or harming the baby, which need sensitive and prompt professional assessment [1,2].

Some people experience relatively little sadness but prominent anxiety, irritability or loss of pleasure. The absence of a stereotypical symptom pattern does not exclude PPD. Depression is not a measure of parental love or ability; it is a health condition that deserves treatment.

Postpartum psychosis: a psychiatric emergency

Postpartum psychosis is different from ordinary baby blues or nonpsychotic depression. Possible features include hallucinations, fixed false beliefs (delusions), severe confusion, paranoia, mania, extreme agitation or markedly reduced need for sleep. Symptoms can appear suddenly and can make a person unable to assess danger reliably. The National Institute of Mental Health (NIMH) identifies postpartum psychosis as a psychiatric emergency requiring immediate hospital-level evaluation [1].

Call local emergency services or go to an emergency department immediately if postpartum psychosis is suspected, or if a person has an active plan or intent to harm themselves or another person. Ensure the infant is cared for by a responsible adult while urgent help is arranged; do not leave a severely confused or psychotic patient to manage alone.

Unwanted intrusive harm thoughts can also occur with postpartum anxiety or OCD, where the thoughts are typically distressing, unwanted and inconsistent with the person’s intentions. These require proper assessment but are not automatically evidence of psychosis or intent. Clinicians distinguish these states through careful questioning about insight, beliefs, intent and functioning [2].

Risk factors and possible causes

Perinatal depression results from interacting biological, psychological and social factors. Hormonal changes after delivery, sleep disruption, previous depression or anxiety, a history of bipolar disorder, a difficult pregnancy or delivery, inadequate support, financial stress and intimate partner violence may contribute [1,2].

Some people develop PPD without any recognized risk factor. It is not caused simply by a shortage of one neurotransmitter or by poor parenting. Because bipolar disorder changes medication decisions and postpartum psychosis risk, a clinician should ask about previous manic or hypomanic episodes before prescribing an antidepressant.

How is postpartum depression identified?

The American College of Obstetricians and Gynecologists (ACOG) recommends systematic screening for depression and anxiety during pregnancy and after childbirth, using a validated tool followed by diagnostic assessment when the result is concerning [2]. Common tools include the Edinburgh Postnatal Depression Scale (EPDS) and Patient Health Questionnaire-9 (PHQ-9).

These questionnaires provide useful signals and help monitor recovery but do not establish the diagnosis by themselves. The clinician evaluates symptom duration, severity, suicidal thoughts, bipolar symptoms, psychosis, sleep, support and medical causes such as thyroid disease or anemia when indicated. A person can seek help at any postpartum visit or between scheduled appointments.

Treatment depends on severity, preference and safety

Clinical situation Potential approach
Mild or moderate PPD CBT or interpersonal psychotherapy (IPT), practical support and follow-up; medication when appropriate.
Moderate to severe PPD Psychotherapy plus an SSRI or other tailored medication; assess functioning and safety.
Selected adults needing PPD-specific pharmacotherapy Specialist consideration of oral zuranolone or other locally available options.
Psychosis, mania, active suicidal intent or immediate danger Emergency psychiatric evaluation; possible hospitalization and specialized treatment.

ACOG advises that clinicians should not withhold or discontinue psychiatric medication solely because the patient is pregnant or breastfeeding. Risk assessment includes the potential effects of untreated depression, infant-care safety, the particular drug and patient preferences [3].

Psychotherapy: CBT and interpersonal therapy

Cognitive behavioral therapy (CBT) helps identify patterns of thinking and behavior that maintain low mood and anxiety. Interpersonal psychotherapy (IPT) addresses relationships, life transitions and support during the move into parenthood. Both have evidence for perinatal depression and may be offered individually, in groups or through suitable remote services [1,3].

Therapy can include addressing sleep disruption, support with infant care, overwhelming responsibilities and access to childcare. It should be adapted to cultural and personal context, and may involve a partner or trusted supporter when the patient wishes. Social support alone is not a substitute for needed clinical treatment in more severe depression.

SSRIs: what should be considered?

Selective serotonin reuptake inhibitors (SSRIs) are frequently used for perinatal depression when medication is appropriate. Selection considers prior response, severity, adverse effects, breastfeeding, drug interactions and other conditions. ACOG supports SSRIs as first-line pharmacotherapy for perinatal depression in suitable patients, with sertraline or escitalopram reasonable options when no previous effective agent is known [3].

SSRIs usually take several weeks to reach full benefit, although some symptoms can improve sooner. Common adverse effects include nausea, loose stools, sleep changes and sexual dysfunction. Monitor for new agitation, suicidal thoughts or symptoms of mania, particularly after initiation or dose changes. Do not abruptly stop a prescribed antidepressant without discussing the plan with the treating clinician.

Breastfeeding while taking antidepressants

Breastfeeding and effective depression treatment can often coexist. The NIH LactMed database considers sertraline a preferred antidepressant during breastfeeding, because concentrations in milk are low and infant serum levels are usually undetectable [4]. Drug choice still depends on the full circumstances, especially prematurity, infant health and maternal response.

Monitor infants as advised for unusual sedation, feeding difficulty, irritability or poor weight gain, especially when several sedating medicines are used or the baby is premature. A person doing well on another medication may not need to switch automatically; the risks of a destabilizing change should be considered with their maternity and mental-health team [3,4].

Zuranolone: an oral postpartum depression treatment

Zuranolone (Zurzuvae) is an oral GABA-A receptor positive allosteric modulator approved by the US Food and Drug Administration (FDA) in 2023 for postpartum depression in adults. The labeled regimen is 50 mg once daily in the evening for 14 days with fat-containing food, with alternative dosing for certain interactions or tolerability circumstances [5]. It is not a routine treatment for every postpartum patient; selection requires professional assessment and access.

The FDA label includes a boxed warning about impaired driving and hazardous activities: patients should not drive or operate hazardous machinery for at least 12 hours after each dose, even when they do not feel impaired. Adverse effects may include sleepiness, dizziness, fatigue and impaired alertness. Clinicians must review other CNS depressants, potential drug interactions, pregnancy potential and childcare safety [5].

Breastfeeding data remain limited. The 2026 FDA label reports low levels of zuranolone in breast milk from a small study but lacks direct outcome data in exposed breastfed infants. Decisions about breastfeeding, infant monitoring and the medication should use shared decision-making rather than claiming either absolute safety or automatic need to stop breastfeeding [5,6].

What about brexanolone?

Brexanolone is an intravenous neuroactive steroid previously used for severe PPD in a supervised setting. It requires extensive monitoring due to sedation and loss-of-consciousness risks, and its availability differs by country and over time. It should not be presented as a convenient outpatient pill or assumed to be locally available. Current treatment selection should consider what is licensed and accessible [3].

Practical support that can improve recovery

  • Arrange a reliable adult to share infant care so that the parent can obtain protected sleep.
  • Offer support with food, household tasks and transport to appointments.
  • Provide nonjudgmental listening; do not dismiss symptoms as normal adjustment or a failure of effort.
  • Identify financial stress, intimate partner violence or isolation and connect with appropriate services.
  • Support adherence to psychotherapy and medication, including follow-up visits.
  • Include the patient in choices about breastfeeding and treatment rather than imposing a single approach.

PPD can also affect fathers and non-birthing partners, who may benefit from their own screening and care. Family support matters, but the person experiencing depression remains central to treatment decisions [1,2].

Frequently asked questions

How long do baby blues last?

Usually no more than about two weeks. Persistent or more severe symptoms warrant assessment [1].

Can depression begin several months after birth?

Yes. Symptoms can begin during pregnancy or at any point across the first postpartum year [1,2].

Is postpartum psychosis the same as postpartum depression?

No. Psychosis with delusions, hallucinations or marked confusion is a psychiatric emergency [1].

Is sertraline compatible with breastfeeding?

Often yes. LactMed considers it a preferred antidepressant during lactation, with individual assessment and infant monitoring [4].

Can zuranolone affect driving?

Yes. The FDA warns not to drive for at least 12 hours after each dose [5].

Should antidepressants be stopped immediately after delivery?

No. Treatment should be continued or adjusted using an individualized plan rather than stopped solely because of lactation [3].

Key takeaways

Postpartum depression is treatable and deserves prompt attention. Screening, CBT/IPT, carefully selected antidepressants and practical support can improve recovery. Postpartum psychosis and immediate safety concerns require emergency care. Treatment choices during breastfeeding and options such as zuranolone call for careful shared decisions.

References

  1. National Institute of Mental Health. Perinatal depression. NIH; accessed 8 Nov 2026.
  2. American College of Obstetricians and Gynecologists. Screening and diagnosis of mental health conditions during pregnancy and postpartum. Obstet Gynecol. 2023. Clinical Practice Guideline No. 4.
  3. American College of Obstetricians and Gynecologists. Treatment and management of mental health conditions during pregnancy and postpartum. Obstet Gynecol. 2023;141:1262–1288. doi:10.1097/AOG.0000000000005202.
  4. National Library of Medicine. Sertraline. Drugs and Lactation Database (LactMed). Updated August 2026.
  5. US Food and Drug Administration. Zurzuvae (zuranolone) prescribing information. Revised 2026.
  6. American College of Obstetricians and Gynecologists. Clinical practice update on zuranolone and brexanolone for postpartum depression. 2025/2026.

Medical disclaimer: This article provides education, not an individual diagnosis or prescription. Postpartum psychosis, suicidal intent, thoughts of harming another person with intent, or inability to remain safe require emergency evaluation. Medication decisions in pregnancy and lactation need qualified professional care.

Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *